Colorado-based Flagship Biosciences, which focuses on spatial biology and biomarker analytics services has acquired Interpace Biosciences’ Pharma Solutions (IPS) division for an undisclosed price.
The combo gives Flagship a full range of biomarker lab and analytic services to advance precision therapeutic development and adds a state-of-the-art laboratory in Research Triangle Park, North Carolina, the company said in a press release.
The integration of IPS will support clinical trials and diagnostic development in immuno-oncology, hematology, solid tumors, and various non-oncology sectors. Flagship’s services will now include advanced molecular biomarker solutions, flow cytometry, cytogenetics, genomics, and bioinformatics solutions. The addition of new genomic profiling capabilities expands biomarker characterization and improves patient stratification for clinical trials and treatment selection, it said.
The deal is part of the investment strategy in Flagship from Ampersand Capital Partners, BroadOak Capital Partners, and Research Corporation Technologies.
“This will allow our customers to gain deeper insights into their clinical projects through multiple biomarker testing paradigms with cohesive data and analytical capabilities, managed in a simplified project workflow,” Trevor Johnson, Flagship’s chief executive, said in a statement.
In February, Flagship announced a partnership with Paige, an AI-based diagnostic software company, in which it got access to the latter’s software that quantifies PD-L1 expression in immunohistochemistry tissue samples.